227 related articles for article (PubMed ID: 35192139)
1. Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.
Pugh-Toole M; Nicolela AP; Nersesian S; Leung BM; Boudreau JE
Curr Treat Options Oncol; 2022 Feb; 23(2):210-226. PubMed ID: 35192139
[TBL] [Abstract][Full Text] [Related]
2. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
Gonzalez VD; Huang YW; Delgado-Gonzalez A; Chen SY; Donoso K; Sachs K; Gentles AJ; Allard GM; Kolahi KS; Howitt BE; Porpiglia E; Fantl WJ
Cell Rep; 2021 Aug; 36(9):109632. PubMed ID: 34469729
[TBL] [Abstract][Full Text] [Related]
3. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
[TBL] [Abstract][Full Text] [Related]
4. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer treatment and natural killer cell-based immunotherapy.
Fan Z; Han D; Fan X; Zhao L
Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
[TBL] [Abstract][Full Text] [Related]
6. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
7. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study.
Lee GH; An HJ; Kim TH; Kim G; Park KS; Park H; Lee TH; Kwon AY
Yonsei Med J; 2021 Apr; 62(4):288-297. PubMed ID: 33779082
[TBL] [Abstract][Full Text] [Related]
9. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
11. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
[TBL] [Abstract][Full Text] [Related]
12. Stem-cell based, machine learning approach for optimizing natural killer cell-based personalized immunotherapy for high-grade ovarian cancer.
Esmail S; Danter WR
FEBS J; 2022 Feb; 289(4):985-998. PubMed ID: 34582617
[TBL] [Abstract][Full Text] [Related]
13. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
14. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell-mediated immunosurveillance of human cancer.
Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
[TBL] [Abstract][Full Text] [Related]
16. Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
Henriksen JR; Donskov F; Waldstrøm M; Jakobsen A; Hjortkjaer M; Petersen CB; Dahl Steffensen K
Acta Oncol; 2020 Jun; 59(6):652-659. PubMed ID: 31931651
[No Abstract] [Full Text] [Related]
17. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
18. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.
Truxova I; Kasikova L; Hensler M; Skapa P; Laco J; Pecen L; Belicova L; Praznovec I; Halaska MJ; Brtnicky T; Salkova E; Rob L; Kodet R; Goc J; Sautes-Fridman C; Fridman WH; Ryska A; Galluzzi L; Spisek R; Fucikova J
J Immunother Cancer; 2018 Dec; 6(1):139. PubMed ID: 30526667
[TBL] [Abstract][Full Text] [Related]
19. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
20. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]